- A revolutionary genomic test, Prosigna, could spare millions of breast cancer patients from chemotherapy, a clinical trial has shown.
- The Optima trial observed over 4,400 women and men aged 40 or older with hormone-sensitive breast cancer, who would typically receive chemotherapy.
- Participants with a low Prosigna score, indicating low gene activity, were treated with hormone therapy alone.
- Those with high scores received chemotherapy and hormone therapy.
- Results showed that five years after treatment, 93.6 per cent of low-scoring patients treated with hormone therapy alone were alive and recurrence-free, comparable to the 94.8 per cent who also received chemotherapy.
IN FULL
